Use of post-exposure prophylaxis after occupational exposure to Zaire ebolavirus

Authors

Karen K. Wong, U.S. Centers for Disease Control and Prevention, AtlantaFollow
Richard T. Davey, National Institutes of Health, Bethesda, Maryland
Angela L. Hewlett, University of Nebraska Medical Center
Colleen S. Kraft, Emory University, Atlanta
Aneesh K. Mehta, Emory University, Atlanta
Mark J. Mulligan, Emory University, Atlanta
Allison Beck, Emory University, Atlanta
William Dorman, US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland
Christopher J. Kratochvil, University of Nebraska Medical Center, Omaha
Lilin Lai, Emory University, Atlanta
Tara N. Palmore, National Institutes of Health, Bethesda, Maryland
Susan Rogers, Emory University, Atlanta, Georgia
Philip W. Smith, University of Nebraska Medical Center, OmahaFollow
Anthony F. Suffredini, Critical Care Medicine Department, Clinical Center, National Institutes of Health
Mark Wolcott, US Army Medical Research Institute of Infectious Diseases, Frederick
Ute Ströher, U.S. Centers for Disease Control and Prevention, Atlanta
Timothy M. Uyeki, U.S. Centers for Disease Control and Prevention, AtlantaFollow

Date of this Version

2016

Citation

Clinical Infectious Diseases (2016) doi: 10.1093/cid/ciw256.

Comments

US government work

Abstract

From September 2014–April 2015, six persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agents rVSV-ZEBOV or TKM-100802 for post-exposure prophylaxis and were monitored in the U.S. All patients experienced self-limited symptoms after PEP; none developed Ebola virus disease.